Axelle Septembre-Malaterre

Dr. Axelle Septembre-Malaterre

Université de La Réunion, Unité de recherche Etudes Pharmaco-Immunologie (EPI), CHU La Réunion site Félix Guyon, Allée des Topazes, CS11021, 97400 Saint Denis de La Réunion
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Food Research International
Verified
Journal Article
Closed access
ASAxelle Septembre-Malaterre
Axelle Septembre-Malaterre
Fabienne RemizeFabienne Remize
Fabienne Remize
PPPatrick Poucheret
Patrick Poucheret

Verified
Journal Article
Open access
PDF file
ASAxelle Septembre-Malaterre
Axelle Septembre-Malaterre
LMLALARIZO RAKOTO Mahary
LALARIZO RAKOTO Mahary
CMClaude MARODON
Claude MARODON
YBYOSRA BEDOUI
YOSRA BEDOUI
JNJessica Nakab
Jessica Nakab
Philippe GasquePhilippe Gasque
Philippe Gasque
Traditional remedies have been used for thousand years for the prevention and treatment of infectious diseases, particularly in developing countries. Of growing interest, the plant Artemisia annua, known for its malarial properties, has been studied for its numerous biological activities including metabolic, anti-tumor, anti-microbial and immunomodulatory properties. Artemisia annua is very rich in secondary metabolites such as monoterpenes, sesquiterpenes and phenolic compounds, of which the biological properties have been extensively studied. The purpose of this review is to gather and describe the data concerning the main chemical components produced by Artemisia annua and to describe the state of the art about the biological activities reported for this plant and its compounds beyond malaria.

20 April 2016 in BioFactors
Verified
Journal Article
Closed access
PDF file
ASAxelle Septembre-Malaterre
Axelle Septembre-Malaterre
FSFanny Le Sage
Fanny Le Sage
SHSarah Hatia
Sarah Hatia
ACAurélie Catan
Aurélie Catan
LJLaurent Janci
Laurent Janci
MGMarie-Paule Gonthier
Marie-Paule Gonthier

17 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
YBYosra Bedoui
Yosra Bedoui
ASAxelle Septembre-Malaterre
Axelle Septembre-Malaterre
CGClaude Giry
Claude Giry
MJMarie-Christine Jaffar-Bandjee
Marie-Christine Jaffar-Bandjee
JSJimmy Selambarom
Jimmy Selambarom
Philippe GasquePhilippe Gasque
Philippe Gasque
Patients following infection by chikungunya virus (CHIKV) can suffer for months to years from arthralgia and arthritis. Interestingly, methotrexate (MTX) a major immune-regulatory drug has proved to be of clinical benefit. We have previously shown that CHIKV can persist in the joint of one patient 18 months post-infection and plausibly driving chronic joint inflammation but through ill-characterized mechanisms. We have pursued our investigations and report novel histological andin vitrodata arguing for a plausible role of a COX-2-mediated inflammatory response post-CHIKV. In the joint, we found a robust COX-2 staining on endothelial cells, synovial fibroblasts and more prominently on multinucleated giant cells identified as CD11c+ osteoclasts known to be involved in bone destruction. The joint tissue was also strongly stained for CD3, CD8, CD45, CD14, CD68, CD31, CD34, MMP2, and VEGF (but not for NO synthase and two B cell markers). Dendritic cells were rarely detected. Primary human synovial fibroblasts were infected with CHIKV or stimulated either by the synthetic molecule polyriboinosinic:polyribocytidylic acid (PIC) to mimic chronic viral infection or cytokines. First, we found that PIC and CHIKV enhanced mRNA expression of COX-2. We further found that PIC but not CHIKV increased the mRNA levels of cPLA2α and of mPGES-1, two other central enzymes in PGE2 production. IFNβ upregulated cPLA2α and COX-2 transcription levels but failed to modulated mPGES-1 mRNA expression. Moreover, PIC, CHIKV and IFNβ decreased mRNA expression of the PGE2 degrading enzyme 15-PGDH. Interestingly, MTX failed to control the expression of all these enzymes. In sharp contrast, dexamethasone was able to control the capacity of pro-inflammatory cytokines, IL-1β as well as TNFα, to stimulate mRNA levels of cPLA2α, COX-2 and mPGES-1. These original data argue for a concerted action of CHIKV (including viral RNA) and cytokines plausibly released from recruited leukocytes to drive a major COX-2-mediated PGE2 proinflammatory responses to induce viral arthritis.

7 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FAFranck Ah-Pine
Franck Ah-Pine
ASAxelle Septembre-Malaterre
Axelle Septembre-Malaterre
YBYOSRA BEDOUI
YOSRA BEDOUI
MKMohamed Khettab
Mohamed Khettab
JNJames Neal
James Neal
Philippe GasquePhilippe Gasque
Philippe Gasque
The complement (C) innate immune system has been shown to be activated in the tumor microenvironment of various cancers. The C may support tumor growth by modulating the immune response and promoting angiogenesis through the actions of C anaphylatoxins (e.g., C5a, C3a). The C has important double-edged sword functions in the brain, but little is known about its role in brain tumors. Hence, we analyzed the distribution and the regulated expression of C3a and its receptor C3aR in various primary and secondary brain tumors. We found that C3aR was dramatically upregulated in Grade 4 diffuse gliomas, i.e., glioblastoma multiforme, IDH-wildtype (GBM) and astrocytoma, IDH-mutant, Grade 4, and was much less expressed in other brain tumors. C3aR was observed in tumor-associated macrophages (TAM) expressing CD68, CD18, CD163, and the proangiogenic VEGF. Robust levels of C3a were detected in the parenchyma of GBM as a possible result of Bb-dependent C activation of the alternative C pathway. Interestingly, in vitro models identified TGF-β1 as one of the most potent growth factors that upregulate VEGF, C3, and C3aR in TAM (PMA-differentiated THP1) cell lines. Further studies should help to delineate the functions of C3a/C3aR on TAMs that promote chemotaxis/angiogenesis in gliomas and to explore the therapeutic applications of C3aR antagonists for brain tumors.

18 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAxelle Septembre-Malaterre
Axelle Septembre-Malaterre
YBYosra Bedoui
Yosra Bedoui
CGClaude Giry
Claude Giry
PGPhilippe Gasque
Philippe Gasque
PGPascale Guiraud
Pascale Guiraud
JSJimmy Sélambarom
Jimmy Sélambarom
O’nyong-nyong virus is an alphavirus closely related to chikungunya virus, causing arthralgia, rash and fever. Alphaviruses mainly target synovial fibroblasts and persists in the joints of patients, possibly leading to chronic arthritis. To date, no specific antiviral treatment is available for ONNV infection and induced-inflammation. Primary human synovial fibroblasts cells were used to assess infection by ONNV and the resulting cytokine responses. Phenolics (gallic acid, caffeic acid and chlorogenic acid, curcumin and quercetin) and a curcuminoids-rich extract from turmeric were tested for their antiviral and anti-inflammatory capacities. We showed that infection occurred in HSF cells and increased gene expression and protein secretion of two major proinflammatory CCL-2 and IL-1β markers. In ONNV-infected HSF cells (MOI 1), we found that non-cytotoxic concentrations of phenolics (10 µM) reduced the level of viral RNA (E1, E2, nsP1, nsP2) and downregulated CCL-2 and IL-1β expression and secretion. These results highlighted the high value of the flavonol quercetin to reduce viral RNA levels and inflammatory status induced by ONNV in HSF cells.